当前位置: 首页 > 期刊 > 《中国当代医药》 > 2011年第8期 > 正文
编号:12080068
间充质干细胞的免疫原性及其在移植中的应用(1)
http://www.100md.com 2011年3月15日 杨晋东,赵振林
第1页

    参见附件(1895KB,2页)。

     [摘要] 目的:探讨研究间充质干细胞的免疫原性以及rMSCs在临床移植中的应用。方法:使用免疫组化方法鉴定rMSCs表面rat LA-ABC、rat LA-DR、CD80、CD86分子,并使用流式细胞术检测其含量;免疫组化法rMSC表面MHCI、Ⅱ类分子的鉴定。结果:rat LA-ABC分子在大鼠间充质干细胞的表面的表达率为13.08%,同时rat LA-DR以及CD80、CD86分子在大鼠间充质干细胞的表面均未有不表达,而外周血淋巴细胞PBLs的表面对rat LA-ABC、rat LA-DR、CD80、CD86这些分子的表达率分别为92.71%、22.39%、14.08%、9.03%。光学显微镜下观察细胞染色情况,细胞核中有棕黄染色者为阳性细胞。结论:MSC具有多向分化潜能,特性稳定;MSC不表达MHCⅡ类分子,不表达或极低表达MHCI类分子,能逃脱宿主免疫系统的排斥,异基因MSC可以进入宿主细胞,并能长期存在。MSC具有低免疫原性,临床上大大降低移植排斥及移植物抗宿主病,提高临床移植的存活率。

    [关键词] 间充质干细胞;免疫原性;移植;临床应用

    [中图分类号] R-332 [文献标识码]A[文章编号]1674-4721(2011)03(b)-012-02

    Mesenchymal stem cells and their immunogenicity in transplantation research

    YANG Jindong; ZHAO Zhenlin

    Department of General Surgery, the Second Hospital of Shanxi Medicial Univerdity, Taiyuan 030001, China

    [Abstract] Objective: To investigate the mesenchymal stem cells of the immunogenicity and rMSCs in clinical transplantation. Methods: Immunohistochemistry identified rMSCs surface rat LA-ABC, rat LA-DR, CD80, CD86 molecules, and using flow cytometry and their contents; immunohistochemistry rMSC surface MHCI, Ⅱ molecule identification. Results: rat LA-ABC molecules in rat mesenchymal stem cell surface expression was 13.08%, while rat LA-DR and CD80, CD86 molecules in rat mesenchymal stem cells are not expressed on the surface were not suits the week the surface of blood lymphocytes PBLs of rat LA-ABC, rat LA-DR, CD80, CD86 expression of these molecules were 92.71%, 22.39%, 14.08%, 9.03%. Cells were observed under light microscope staining, nuclei were stained in brown positive cells. Conclusion: MSC have multilineage differentiation potential, characteristics and stability; MSC did not express MHC Ⅱ molecules, did not express or very low expression of MHCI molecules, can escape the host immune system rejection, allogeneic MSC can enter the host cell, and long-term existence. MSC with low immunogenicity, greatly reduce the clinical transplant rejection and graft versus host disease, improve the survival rate of clinical transplantation.

    [Key words] Bone marrow-derived mesenchymal stem cells; Immunogenicity; Transplant; Clinical appication ......

您现在查看是摘要介绍页,详见PDF附件(1895KB,2页)